Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2016 | The issue of drug cost: transparent pricing & acceptable profit margins

Anton Hagenbeek • 9 Jun 2016
EHA 2016
General

Anton Hagenbeek, MD, PhD from the University of Amsterdam, Amsterdam, Netherlands talks about the issue of drug costs in oncology. Drug combinations are effective but particulalry costly according to Prof. Hagenbeek. He argues that there is an urgent need to talk to the biotech companies producing the drugs and to agree on transparent pricing of these drugs and socially acceptable profit margins.
Recorded at the European Hematology Association (EHA) 2016 Annual Congress in Copenhagen, Denmark.

More from Anton Hagenbeek

23:19
12th International Workshop on Non-Hodgkin Lymphoma (iwNHL) 2014: Day 2 meeting highlights
Anton Hagenbeek et al. • 9 Apr 2015
16:39
iwNHL 2015 roundtable: The changing treatment landscape for non-Hodgkin lymphoma
Andrew Zelenetz et al. • 3 Oct 2015
2:56
Immuno-oncology opportunities for the treatment of lymphoma
Anton Hagenbeek • 4 Dec 2015
2:18
Brentuximib vedotin therapy for Hodgkin lymphoma
Anton Hagenbeek • 9 Dec 2014

Related Videos

0:58
Hematological manifestations associated with primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
1:44
PHOEBUS trial: oral fecal microbiotherapy for increasing OS in patients undergoing alloSCT
Florent Malard • 11 Apr 2024
2:24
Manipulating the gut microbiome to improve outcomes of alloSCT for hematological malignancies
Florent Malard • 11 Apr 2024
3:29
PTCy as GvHD prophylaxis: side effects, optimizing the dose, and the effect of dose-reduction
Rémy Duléry • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals